Riskpilot← Back to searchSign inGet full accessAmellnova AB
ABDissolvedOrg 5567829444Manufacture of pharmaceutical preparations · NACE 2120Est. 20090 employees
Revenue 2018
SEK 3,3M
+29% vs 2017
EBITDA margin
21.0%
+369% vs 2017
Equity ratio
66.1%
Financial strength
Net profit 2018
SEK 521K
+392% vs 2017
| Revenue | SEK 3,3M | +29% |
| EBITDA | SEK 685K | +369% |
| Net profit | SEK 521K | +392% |
| Total assets | SEK 940K | -21% |
| Equity | SEK 621K | +34% |
| Employees | 0 | — |
Legal name
Amellnova AB
Org number
5567829444
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
25 maj 2009
Share capital
SEK 0
Employees
0
VAT registered
No
Audit selected
No
Last report
2018-04-30
Financial year
January – December
Company purpose
Bolaget ska bedriva utveckling, produktion och marknadsföring av läkemedelsprodukter och medicinteknik, medicinsk konsultverksamhet samt idka därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Revenue | 2 249 | 2 519 | 3 259 |
| Staff expenses | — | — | — |
| EBITDA | 50 | 146 | 685 |
| Depreciation & amort. | −111 | −0 | −0 |
| EBIT | −61 | 146 | 685 |
| Net financials | — | — | — |
| Profit before tax | 3 | 146 | 685 |
| Tax | −3 | −40 | −164 |
| Net profit | 0 | 106 | 521 |
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Total assets | 1 068 | 1 192 | 940 |
| Equity | 357 | 464 | 621 |
| Long-term debt | 0 | 0 | 0 |
| Short-term debt | 710 | 729 | 319 |
| Total debt | 710 | 729 | 319 |
EBITDA margin
21.0%
This company
15.8%
Market median
+33% vs market
20162018
Equity ratio
66.1%
This company
38.2%
Market median
+73% vs market
20162018
Return on equity
83.9%
This company
18.4%
Market median
+356% vs market
20162018
Net profit margin
16.0%
This company
8.1%
Market median
+98% vs market
20162018
Asset turnover
3.47×
This company
1.12×
Market median
+210% vs market
20162018
Debt / equity
0.51×
This company
0.62×
Market median
+18% vs market
20162018
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-05-01 – 2018-04-30
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-05-01 – 2017-04-30
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-05-01 – 2016-04-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JH External Signatory | External Signatory | 2019 | — | — |
JK Auditor Substitute | Auditor Substitute | 2019 | — | — |
LM | Audit | 2019 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2019 | — | — | |
| Board of Directors | 2019 | — | — | |
| Chairman | 2019 | — | — | |
| Board of Directors | 2019 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Amellnova AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Johan Henning Lindberg | External Signatory | 0 companies |
| Johanna Katarina Boive | Auditor Substitute | 0 companies |
| Linda Margareta Sandler | Audit | 0 companies |
| Aarne Paalberg | Deputy Board Member | 0 companies |
| Jan Gustav Smith | Board of Directors | 0 companies |
| Leif Carl Gustav Smith | Chairman | 0 companies |
| Claes Lundberg | Board of Directors | 0 companies |